Profile

• 07.2019
  Title of Medical Specialty in Gynecology and Obstetrics
  (Ärztekammer Nordrhein, German Medical Association of North Rhine-Westphalia)
• 10.2015
  PhD.- Doctor of University of Bonn
• 11.2013
  German license to practice medicine
  Medical Degree, Rheinische Fridrich-Wilhelms-Universität Bonn, Germany
• 06.2006
  Greek High School Graduation Certificate and German Graduation Certificate (Deutsches Abitur), German School of Athens (Deutsche Schule Athen)

"Retrospective analysis of perioperative management in neonates with gastroschisis and omphalocele” in the neonatal unit of the University Hospital of Bonn Children’s Hospital
"Retrospektive Analyse des perioperativen Managements von Kindern mit Gastroschisis und Omphalozele"

• 01.11.2019-31.03.2022
  Specialization in chemotherapy - gynecologic oncology at the chemotherapeutic gynecologic oncology center of the University Hospital of Düsseldorf Clinic for Gynecology and Obstetrics
  [IAC (Interdisziplinäres Ambulantes Chemotherapiezentrum), Universitätsfrauenklinik, Düsseldoff, Germany]
• 01.10.2017-30.09.2019
  Obtained title of medical specialty in gynecology and obstetrics at the Gynecology and Obstetrics Clinic of the Hilden certified breast center
  (St. Josef Krankenhaus, Hilden, Germany)
• 01.10.2015-13.06.2017
  Continuation of gynecology and obstetrics specialty at the Gynecology and Obstetric Clinic of Cologne
  (St. Vinzenz Hospital, Köln, Germany)
• 15.01.2014-30.09.2015
  Commencement of gynecology and obstetrics specialty at the University Hospital Bonn’s Gynecology and Obstetrics Clinic
  (Universitätsklinikum Bonn, Zentrum für Geburtshilfe und Frauenheilkunde)

• 12.2021
  Obtained title of specialization in chemotherapy - gynecologic oncology from the Medical Association of North Rhine Westphalia (Ärztekammer Nordrhein)
• 02.2021
  Obtained title of specialization in palliative medicine (Palliativmedizin) from the Medical Association of North Rhine Westphalia (Ärztekammer Nordrhein)

• Breast cancer surgical treatment
• Oncological treatment of breast cancer
• Chemotherapy - gynecologic oncology
• Palliative medicine and symptomatic care in metastatic gynecological cancer

• 12.2021
  Certification in oncology diagnosis and treatment in the field of gynecology
  German Society of Gynecological Oncology (AGO; Arbeitsgemeinschaft Gynäkologische Onkologie)
• 06.2020
  Certification of Good Clinical Practice at the University Hospital of Düsseldorf Clinic for Gynecology and Obstetrics
• 12.2018
  Certification in psychosomatic counseling
  IAN Akademie (Internationale Akademie für Angewandte Akupunktur und Natürliche Heilwesen)
• 02.2018
  Certification of laparoscopic gynecological surgery course attendance
  University Gynecology and Obstetrics Clinic, St. Vinzenz Hospital, Dinslaken of North Rhine-Westphalia
  AGE Grundkurs Laparoskopie der Arbeitsgemeinschaft Gynäkologische Endoskopie, Dr. med. Uhl
• 02.,03., και 11.2018
  Certification of breast ultrasound course attendance
  „6. Rhein-Ruhr Grund-, Aufbau und Abschluss Mammasonographie Kurs“
  Breast Center, Köln-Hohlweide, Prof. Dr. Mathias Warm, Prof. Dr. Sherko Kümmel
• 02., 04. και 11.2014
  Certification of Doppler ultrasound in obstetrics course attendance
  University Hospital Bonn’s Gynecology and Obstetrics Clinic
  Prof. Dr. Gembruch, Prof. Dr. Geipel, Prof. Dr. Berg
  Membership in Societies and Editorial Boards
• Athens Medical Association (A.M.Α)
• North Rhine-Westphalia Medical Association
  (Ärztekammer Nordrhein)
• German Society for Obstetrics and Gynecology
  (Deutsche Gesellschaft für Gynäkologie und Geburtshilfe)
• German Society for Senology (Deutsche Gesellschaft für Senologie)
• German Association for Palliative Medicine and Symptomatic Care (Deutsche Gesellschaft für Palliativmedizin)

• Treatment protocols for women with breast cancer (curable and metastatic), University Gynecology Clinic, Düsseldorf, Germany:
  1) Sascia (GBG 102): Phase III postneoadjuvant study evaluating Sacituzumab Govitecan, an Antibody Drug Conjugate in primary HER2-negative breast cancer patients with high relapse risk after standard neoadjuvant treatment
  2) neoMono: An adaptive randomized neoadjuvant, Phase II, two arm trial in triple-negative breast cancer comparing a mono Atezolizumab window followed by a Atezolizumab-Chemotherapy with Atezolizumab-Chemotherapy
  3) AdaptCycle: Adjuvant Dynamic marker-Adjusted Personalized Therapy comparing endocrine therapy plus Ribociclib vs. chemotherapy in intermediate risk, HR+/HER2-early breast cancer
  4) GeparDouze: A randomized douple-blind Phase III clinical trial of neoadjuvant therapy with Atezolizumab or placebo in patients with triple negative breast cancer followed by adjuvant Atezolizumab or placebo
  5) Detect V/Chavendo: A multicenter, randomized Phase III Study to compare Chemo-vs. Endocrine Therapy in Combination with Dual HER2-targeted therapy of Herceptin® (Transtuzumab) and Perjeta® (Pertuzumab) plus Kisqali® (Ribociclib) in patients with HER2 positive and hormone-receptor positive metastatic cancer.
  6) PRECYCLE: Multicenter, randomized Phase IV intergroup trial to evaluate the impact of eHealth-based Patient Reported Outcome (PRO) Assessment on Quality of Life in patients with hormone receptor positive, HER2 negative locally advanced or metastatic breast cancer treated with Palbociclib and an aromatase inhibitor- or Palbociclib and Fulvestrant.
  7) Serena-2: A randomized, open-label, parallel group, multicenter phase 2 study comparing the efficacy and safety of oral AZD9833 vs. fulvestrant in women with advanced ER-positive HER2-negative breast cancer.
  8) Keylink 009: A phase II/III, open-label, randomized study of pembrolizumab plus olaparib vs. pembrolizumab plus chemotherapy after induction with first-line pembrolizumab plus chemotherapy in patients with locally recurrent inoperable or metastastic triple negative breast cancer (TNBC).
• Ovarian cancer treatment protocols at the University Gynecology and Obstetrics Clinic, Düsseldorf, Germany:
  1) Keylink 001/ENGOT-ov43: A phase III, placebo-and active-controlled trial of pembrolizumab plus chemotherapy with olaparib maintenance for first-line treatment of advanced BRCA-nonmutated epithelial ovarian cancer.
  2) AGO-OVAR 25/GOG-3020: A multicenter, randomized, double-blind, placebo-controlled phase III study in ovarian cancer patients evaluating Rucaparib and Nivolumab as maintenance treatment following response to front-line platinum based chemotherapy.